Research programme: factor Xa inhibitors - Schering-Plough

Drug Profile

Research programme: factor Xa inhibitors - Schering-Plough

Alternative Names: Factor Xa inhibitors research programme - Schering-Plough; Oral anticoagulants research programme - Schering-Plough

Latest Information Update: 26 Sep 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon San Diego LLC
  • Developer Schering-Plough
  • Class
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Deep vein thrombosis; Embolism; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 26 Sep 2002 Corvas International has terminated its involvement in the research collaboration
  • 03 Feb 1999 Preclinical development for Deep vein thrombosis in USA (PO)
  • 03 Feb 1999 Preclinical development for Embolism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top